umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
2016 (English)In: British Journal of Clinical Pharmacology, ISSN 0306-5251, E-ISSN 1365-2125, Vol. 82, no 4, 932-942 p.Article, review/survey (Refereed) Published
Abstract [en]

Palmitoylethanolamide (PEA) has been suggested to have useful analgesic properties and to be devoid of unwanted effects. Here, we have examined critically this contention, and discussed available data concerning the pharmacokinetics of PEA and its formulation. Sixteen clinical trials, six case reports/pilot studies and a meta-analysis of PEA as an analgesic have been published in the literature. For treatment times up to 49days, the current clinical data argue against serious adverse drug reactions (ADRs) at an incidence of 1/200 or greater. For treatment lasting more than 60days, the number of patients is insufficient to rule out a frequency of ADRs of less than 1/100. The six published randomized clinical trials are of variable quality. Presentation of data without information on data spread and nonreporting of data at times other than the final measurement were among issues that were identified. Further, there are no head-to-head clinical comparisons of unmicronized vs. micronized formulations of PEA, and so evidence for superiority of one formulation over the other is currently lacking. Nevertheless, the available clinical data support the contention that PEA has analgesic actions and motivate further study of this compound, particularly with respect to head-to-head comparisons of unmicronized vs. micronized formulations of PEA and comparisons with currently recommended treatments.

Place, publisher, year, edition, pages
2016. Vol. 82, no 4, 932-942 p.
Keyword [en]
adverse drug reactions, clinical trials, inflammation, pain, pharmacokinetics, Palmitoylethanolamide
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:umu:diva-130060DOI: 10.1111/bcp.13020ISI: 000383685700004PubMedID: 27220803OAI: oai:DiVA.org:umu-130060DiVA: diva2:1064806
Available from: 2017-01-13 Created: 2017-01-11 Last updated: 2017-01-13Bibliographically approved

Open Access in DiVA

fulltext(652 kB)32 downloads
File information
File name FULLTEXT01.pdfFile size 652 kBChecksum SHA-512
18470d09ee7d1f3696235ed6a3c1633031e7b969c3ac40b8ba4820396b306e672a9f314c93a8ad10f10546183c3aece5e7e0d9f7ffb5f7d1d0cbabfbb0d1b31a
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Gabrielsson, LindaMattsson, SofiaFowler, Christopher J.
By organisation
Department of Pharmacology and Clinical Neuroscience
In the same journal
British Journal of Clinical Pharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 32 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 37 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf